Answers are grounded in this paper and cite their sources.
HCV re-infection after liver transplantation is constant and accelerated in patients who are PCR-positive at the time of transplantation. Reinfection significantly impairs patient and graft survival [1]. At present, there are limited options available to prevent graft reinfection after transplantation or to successfully treat reinfected patients. Pretransplant antiviral combination therapy with (peg)interferon/ribavirin (PegIFN/RBV) is poorly tolerated and not very effective in patients infected with HCV genotype 1.
No takes yet. Share an insight, caveat, or question.
Ferenci et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: